TriSalus Life Sciences Inc

Insider sales at TriSalus reveal tax‑planned trades, yet big purchases by execs signal confidence in its immunotherapy pipeline and future growth prospects.

Insider buying at TriSalus Life Sciences signals confidence amid volatile share prices—learn how director purchases may spark a rebound.

Insider buying surges at TriSalus Life Sciences after a $40 M offer—executives buy at $4.10, boosting confidence in its liver‑pancreas immunotherapy platform.

TriSalus insider move: Co‑founder Michael Stansky exercises zero‑price stock option, hinting at optimism amid a modestly volatile, pre‑commercial biotech platform targeting liver and pancreas tumors—watch partnerships, trials and capital raises.